Eculizumab, a novel potential treatment for acute kidney injury associated with preeclampsia/HELLP syndrome.

Autor: Elabd, Hatem, Elkholi, Mennallah, Steinberg, Lewis, Acharya, Anjali
Zdroj: BMJ Case Reports; 9/5/2019, Vol. 12 Issue 9, p1-4, 4p, 3 Charts, 1 Graph
Abstrakt: The kidney is one of the major organs affected in preeclampsia. There is evidence suggesting a role for excessive complement activation in the pathogenesis of preeclampsia. We describe a case of preeclampsia with severe features, including HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) and acute kidney injury (AKI) that developed following caesarian section. The patient required renal replacement therapy. A trial of daily plasma exchange was not effective. The patient received a single dose of eculizumab, a humanised monoclonal IgG antibody that binds to complement protein C5. One week post administration of eculizumab, there was significant improvement in haematologic, hepatic and renal function. Blood pressure had normalised and renal replacement therapy was discontinued. The use of eculizumab may have contributed to recovery of kidney function further supporting the role of complement activation in the pathogenesis of preeclampsia and associated AKI. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index